Intra-Cellular Therapies (ITCI) Upgraded to “Sell” at BidaskClub

BidaskClub upgraded shares of Intra-Cellular Therapies (NASDAQ:ITCI) from a strong sell rating to a sell rating in a report published on Friday morning.

Several other research firms have also commented on ITCI. Cowen reiterated an outperform rating and issued a $27.00 price objective (up from $20.00) on shares of Intra-Cellular Therapies in a research report on Friday, September 8th. BTIG Research reiterated a buy rating and issued a $36.00 price objective on shares of Intra-Cellular Therapies in a research report on Friday, September 8th. SunTrust Banks reiterated a hold rating and issued a $22.00 price objective (up from $16.00) on shares of Intra-Cellular Therapies in a research report on Friday, September 8th. Piper Jaffray Companies upgraded shares of Intra-Cellular Therapies from a neutral rating to an overweight rating and boosted their price objective for the stock from $14.00 to $33.00 in a research report on Thursday, September 7th. Finally, ValuEngine lowered shares of Intra-Cellular Therapies from a sell rating to a strong sell rating in a research report on Wednesday, September 27th. Two analysts have rated the stock with a sell rating, one has issued a hold rating and nine have given a buy rating to the company’s stock. The stock has a consensus rating of Buy and a consensus price target of $25.56.

Intra-Cellular Therapies (NASDAQ:ITCI) traded up $0.13 during trading hours on Friday, hitting $17.47. 989,441 shares of the stock were exchanged, compared to its average volume of 443,629. Intra-Cellular Therapies has a fifty-two week low of $7.85 and a fifty-two week high of $22.67. The firm has a market cap of $953.47, a PE ratio of -7.98 and a beta of 0.72.

Intra-Cellular Therapies (NASDAQ:ITCI) last posted its quarterly earnings results on Wednesday, November 8th. The biopharmaceutical company reported ($0.53) earnings per share for the quarter, hitting the Zacks’ consensus estimate of ($0.53). Intra-Cellular Therapies had a negative net margin of 28,038.35% and a negative return on equity of 27.40%. The business had revenue of $0.03 million for the quarter, compared to analysts’ expectations of $0.06 million. During the same period in the prior year, the company posted ($0.70) EPS. The business’s revenue for the quarter was up 675.0% on a year-over-year basis. sell-side analysts forecast that Intra-Cellular Therapies will post -2.13 earnings per share for the current fiscal year.

In other Intra-Cellular Therapies news, Chairman Sharon Mates sold 11,257 shares of the company’s stock in a transaction dated Friday, January 5th. The shares were sold at an average price of $17.08, for a total value of $192,269.56. Following the transaction, the chairman now directly owns 1,099,964 shares in the company, valued at approximately $18,787,385.12. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, CFO Lawrence J. Hineline sold 3,192 shares of the company’s stock in a transaction dated Thursday, January 4th. The shares were sold at an average price of $15.67, for a total transaction of $50,018.64. Following the completion of the transaction, the chief financial officer now owns 68,686 shares in the company, valued at $1,076,309.62. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 42,034 shares of company stock worth $673,564. 19.80% of the stock is owned by insiders.

Large investors have recently added to or reduced their stakes in the business. Russell Investments Group Ltd. purchased a new position in Intra-Cellular Therapies in the 3rd quarter valued at about $101,000. SG Americas Securities LLC purchased a new position in Intra-Cellular Therapies in the 2nd quarter valued at about $103,000. Quantbot Technologies LP lifted its holdings in Intra-Cellular Therapies by 233.1% in the 3rd quarter. Quantbot Technologies LP now owns 8,614 shares of the biopharmaceutical company’s stock valued at $135,000 after purchasing an additional 6,028 shares in the last quarter. Fred Alger Management Inc. purchased a new position in Intra-Cellular Therapies in the 2nd quarter valued at about $161,000. Finally, Dynamic Technology Lab Private Ltd purchased a new position in Intra-Cellular Therapies in the 3rd quarter valued at about $244,000. Institutional investors own 74.47% of the company’s stock.

ILLEGAL ACTIVITY WARNING: “Intra-Cellular Therapies (ITCI) Upgraded to “Sell” at BidaskClub” was posted by Community Financial News and is the sole property of of Community Financial News. If you are viewing this news story on another domain, it was copied illegally and reposted in violation of US and international copyright legislation. The original version of this news story can be viewed at https://www.com-unik.info/2018/01/06/intra-cellular-therapies-itci-upgraded-to-sell-at-bidaskclub.html.

About Intra-Cellular Therapies

Intra-Cellular Therapies, Inc (ITI) is a biopharmaceutical company. The Company is focused on the discovery and clinical development of small molecule drugs that address underserved medical needs in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms within the central nervous system (CNS).

Analyst Recommendations for Intra-Cellular Therapies (NASDAQ:ITCI)

What are top analysts saying about Intra-Cellular Therapies? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Intra-Cellular Therapies and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit